Exelixis Company Profile (NASDAQ:EXEL)

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Exelixis, Inc. (NASDAQ:EXEL) released its earnings results on Monday, May, 1st. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. The business had revenue of $80.90 million for the quarter, compared to analyst estimates of $65.23 million. Exelixis had a return on equity of 126.82% and a net margin of 1.37%. Exelixis's revenue was up 425.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.27) earnings per share. View Exelixis' Earnings History.

Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Exelixis.

11 brokers have issued 1-year price targets for Exelixis' shares. Their predictions range from $8.00 to $33.00. On average, they anticipate Exelixis' stock price to reach $19.80 in the next twelve months. View Analyst Ratings for Exelixis.

Here are some recent quotes from research analysts about Exelixis stock:

• 1. Cann analysts commented, "Exelixis, Inc. announced today a settlement of the company’s dispute with Genentech, a member of the Roche Group, concerning the parties’ collaboration for the development and commercialization of Cotellic (cobimetinib). As part of the settlement, effective July 1, 2017, the companies have amended the existing Collaboration Agreement to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016." (7/20/2017)
• 2. According to Zacks Investment Research, "Exelixis received a major boost with the FDA approval of Cabometyx tablets in Apr 2016. Initial uptake of the drug was encouraging and is expected to propel the top line in the forthcoming quarters in 2017. The sequential increase in Cabometyx sales is also a positive. Moreover, Cabometyx was also approved in the EU. Meanwhile, Exelixis is developing cabozantinib in a broad development program and plans to file a supplemental New Drug Application (sNDA) in the third quarter of 2017 for advanced RCC. A potential label expansion will further boost sales. Exelixis also has collaborations with Bristol-Myers and Roche on the development of cabozantinib in combination with immunotherapy agents. Exelixis’ share price outperformed the Zacks classified Biomedical and Genetics industry year to date. However, the company is heavily dependent on Cabometyx for growth now.  Operating expenses are also projected to increase." (7/11/2017)

Exelixis saw a decline in short interest in the month of June. As of June 30th, there was short interest totalling 15,465,148 shares, a decline of 12.5% from the June 15th total of 17,681,775 shares. Based on an average daily trading volume, of 7,594,749 shares, the short-interest ratio is presently 2.0 days. Currently, 5.5% of the company's shares are short sold.

Some companies that are related to Exelixis include TESARO (TSRO), BIOVERATIV INC (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), Intercept Pharmaceuticals (ICPT), BeiGene (BGNE), Juno Therapeutics (JUNO), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), Agios Pharmaceuticals (AGIO), Prothena Co. PLC (PRTA), Axovant Sciences (AXON), AveXis (AVXS), Spark Therapeutics (ONCE) and Aerie Pharmaceuticals (AERI).

Exelixis' management team includes the folowing people:

• Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board, Co-Founder
• Michael M. Morrissey Ph.D., President, Chief Executive Officer, Director
• Christopher J. Senner, Chief Financial Officer, Executive Vice President
• Gisela M. Schwab M.D., President - Product Development and Medical Affairs, Chief Medical Officer
• Peter Lamb Ph.D., Executive Vice President - Scientific Strategy, Chief Scientific Officer
• Jeffrey J. Hessekiel J.D., Executive Vice President, General Counsel, Secretary
• Patrick Haley, Senior Vice President - Commercial
• Charles M. Cohen Ph.D., Independent Director
• Carl B. Feldbaum Esq., Independent Director
• Alan M. Garber M.D. Ph.D., Independent Director

Exelixis' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Handelsbanken Fonder AB (0.12%), Bank of Montreal Can (0.04%), Handelsinvest Investeringsforvaltning (0.03%), Creative Planning (0.03%), Aperio Group LLC (0.02%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Exelixis' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have sold Exelixis stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Exelixis' stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, Handelsinvest Investeringsforvaltning, Capstone Asset Management Co., First Quadrant L P CA, Meeder Asset Management Inc. and Aperio Group LLC. View Insider Buying and Selling for Exelixis.

Shares of Exelixis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Exelixis stock can currently be purchased for approximately $26.99.